Fig. 2From: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro studyPhotograph of the SMD device (MiniFlatPlaSter®) used in this study [17]Back to article page